These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26263187)

  • 41. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.
    de Groot FM; Loos WJ; Koekkoek R; van Berkom LW; Busscher GF; Seelen AE; Albrecht C; de Bruijn P; Scheeren HW
    J Org Chem; 2001 Dec; 66(26):8815-30. PubMed ID: 11749612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
    Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
    Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs.
    Abu Ajaj K; Biniossek ML; Kratz F
    Bioconjug Chem; 2009 Feb; 20(2):390-6. PubMed ID: 19199576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EGFR-targeted prodrug activation using bioorthogonal alkene-azide click-and-release chemistry.
    Fairhall JM; Camilli JC; Gibson BH; Hook S; Gamble AB
    Bioorg Med Chem; 2021 Sep; 46():116361. PubMed ID: 34411983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Self-immolative anthracycline prodrugs for suicide gene therapy.
    Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
    J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-activated prodrug (TAP)-conjugated nanoparticles with cleavable domains for safe doxorubicin delivery.
    Guarnieri D; Biondi M; Yu H; Belli V; Falanga AP; Cantisani M; Galdiero S; Netti PA
    Biotechnol Bioeng; 2015 Mar; 112(3):601-11. PubMed ID: 25220931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyaluronate tethered, "smart" multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin.
    Datir SR; Das M; Singh RP; Jain S
    Bioconjug Chem; 2012 Nov; 23(11):2201-13. PubMed ID: 23039830
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A macromolecular prodrug strategy for combinatorial drug delivery.
    Li NN; Lin J; Gao D; Zhang LM
    J Colloid Interface Sci; 2014 Mar; 417():301-9. PubMed ID: 24407691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
    Abu Ajaj K; Graeser R; Kratz F
    Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
    Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
    Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acid-triggered release of doxorubicin from a hydrazone-linked Gd(3+)-texaphyrin conjugate.
    Lee MH; Kim EJ; Lee H; Park SY; Hong KS; Kim JS; Sessler JL
    Chem Commun (Camb); 2016 Aug; 52(69):10551-4. PubMed ID: 27492744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
    Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
    Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
    Han L; Huang R; Liu S; Huang S; Jiang C
    Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and synthesis of novel azapeptide activators of apoptosis mediated by caspase-9 in cancer cells.
    Bourguet CB; Boulay PL; Claing A; Lubell WD
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3361-5. PubMed ID: 24986663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Caspase-3 inhibitor transiently delays inherited retinal degeneration in C3H mice carrying the rd gene.
    Yoshizawa K; Kiuchi K; Nambu H; Yang J; Senzaki H; Kiyozuka Y; Shikata N; Tsubura A
    Graefes Arch Clin Exp Ophthalmol; 2002 Mar; 240(3):214-9. PubMed ID: 11935279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.
    Kovár M; Kovár L; Subr V; Etrych T; Ulbrich K; Mrkvan T; Loucká J; Ríhová B
    J Control Release; 2004 Sep; 99(2):301-14. PubMed ID: 15380639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent.
    Li N; Li N; Yi Q; Luo K; Guo C; Pan D; Gu Z
    Biomaterials; 2014 Nov; 35(35):9529-45. PubMed ID: 25145854
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin.
    Burke PJ; Koch TH
    Anticancer Res; 2001; 21(4A):2753-60. PubMed ID: 11724351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.